Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$24.46 USD

24.46
2,042,385

-0.40 (-1.61%)

Updated May 10, 2024 04:00 PM ET

After-Market: $24.50 +0.04 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NTLA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Intellia Therapeutics, Inc. [NTLA]

Reports for Purchase

Showing records 101 - 120 ( 277 total )

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

02/24/2022

Company Report

Pages: 7

4Q21: Additional Data From Lead Program on Feb 28th

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

02/24/2022

Company Report

Pages: 6

Awaiting ATTR Data on Monday

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

02/15/2022

Daily Note

Pages: 3

Intellia and ONK Therapeutics Join Forces to Develop Allogeneic CRISPR-Edited NK Cell Therapies

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

02/15/2022

Daily Note

Pages: 4

Natural Killers Get Intellia Inside

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

02/14/2022

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

02/11/2022

Daily Note

Pages: 5

Twin Studies Published in Science Translational Medicine Support Efficacy of Targeting WT-1 Epitopes in Tumors

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

02/04/2022

Daily Note

Pages: 27

Looking into 1Q22, Cash Balance, & Price Target Changes

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 35.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

02/03/2022

Daily Note

Pages: 3

Intellia Acquires Rewrite Therapeutics, Expanding its Formidable Arsenal of Genome Editing Tools

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

02/03/2022

Company Report

Pages: 5

NTLA Calls for a Rewrite

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

01/24/2022

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

01/07/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

01/07/2022

Daily Note

Pages: 5

Intellia Provides Updates on Strategic Priorities and Development Milestones for 2022; Sets Stage for Catalyst Rich-Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

01/07/2022

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

01/06/2022

Company Report

Pages: 7

Intellia Tells All

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

01/06/2022

Company Report

Pages: 8

Outlines Activities for 2022

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

01/05/2022

Daily Note

Pages: 3

Intellia Forms Strategic Partnership With Kyverna to Tackle B Cell-Mediated Autoimmune Diseases

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

01/05/2022

Daily Note

Pages: 3

Intelligent Collaboration with Kyverna

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

01/02/2022

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

12/30/2021

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Intellia Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

12/20/2021

Industry Report

Pages: 5

As CAR-T Programs Scream "Look at Me" During ASH, We Look to the Future Impact of TCR-Ts

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party